|
November 4, 2026
|
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
|
|
October 28, 2026
|
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership
|
|
October 26, 2026
|
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
|
|
October 13, 2026
|
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
|
|
September 1, 2026
|
Enanta Pharmaceuticals to Participate in September Investor Conferences
|
|
August 10, 2026
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
|
|
June 23, 2026
|
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
|
|
June 18, 2026
|
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
|
|
May 28, 2026
|
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
|
|
May 11, 2026
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
|